Furthermore, patients who received radiochemotherapy had excellent efficacy (CR were about 90% in all cases) in primary NPC and cervical lymph nodes, which makes it challenging to predict the therapeutic effect between ERCC1–and ERCC1+ patients. This evidence concerns the gene ERCC1 and nasopharyngeal carcinoma.